Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE, Fernandez M, Patel HB, Barcelo C, Woolley SD, Patel H, Llewellyn S, Abd-Rahman AN, Sharma S, Jain M, Ghoghari A, Di Resta I, Fuchs A, Deni I, Yeo T, Mok S, Fidock DA, Chalon S, Möhrle JJ, Parmar D, McCarthy JS, Kansagra K.
Barber BE, et al. Among authors: abd rahman an.
Lancet Infect Dis. 2022 Jun;22(6):879-890. doi: 10.1016/S1473-3099(21)00679-4. Epub 2022 Mar 2.
Lancet Infect Dis. 2022.
PMID: 35247321
Clinical Trial.